A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

INTRODUCTION: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). However, the efficacy of standard subsequent therapi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Li, Yi, Li, Wei, Gong, Chengcheng, Zheng, Yabin, Ouyang, Quchang, Xie, Ning, Qu, Qing, Ge, Rui, Wang, Biyun
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202336/
https://ncbi.nlm.nih.gov/pubmed/34178122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211022890
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados